Table 2.
Baseline characteristics of enrolled patients
| Variable | Overall cohort N = 40 | Study completers N = 33 | Non-completers N = 7 | P value |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) (median, IQR) | 52.5 (39.5–61) | 53 (43–61) | 44 (30–57) | 0.02 |
| Sex (% male) | 21 (52.5%) | 17 (51.5%) | 4 (57%) | 1.0 |
| Race (% white) | 37 (92.5%) | 30 (90.9%) | 7 (100%) | 1.0 |
| Clinical characteristics | ||||
| Cirrhosis | 12 (30%) | 9 (27.2%) | 3 (42%) | 0.41 |
| Diabetes | 17 (42.5%) | 14 (42.4%) | 3 (42%) | 0.41 |
| Hyperlipidemia or Hypertriglyceridemia | 15(37.5%) | 12(36.6%) | 3 (42%) | 0.41 |
| Hypertension | 17 (42.5%) | 14 (42.4%) | 3 (42%) | 0.41 |
| Depression | 9 (22.5%) | 6 (18.2%) | 3 (42%) | 0.41 |
| Education | ||||
| Elementary/junior high | 1 (2.5%) | 1 (3%) | 0 | 0.53 |
| High school | 13 (32.5%) | 9 (27%) | 4 (57%) | |
| Undergraduate | 17 (42.5%) | 15 (46%) | 2 (29%) | |
| Graduate or higher | 9 (22.5%) | 8 (24%) | 1 (14%) | |
| Physical exam (median, IQR) | ||||
| Waist circumference (inches) | 44 (40.8–48.8) | 42.5 (40.7–46) | 49.6 (41.5–51.5) | 0.001 |
| Truncal obesity | 33 (83%) | 26 (84%) | 7 (100%) | 0.56 |
| Weight (lb) | 209.5 (189.5–250) | 200 (186–236) | 270 (240–301) | 0.006 |
| BMI (kg/m2) | 33.9 (30.4–36.5) | 33.6 (29.6–35.3) | 37.7 (35.5–42.4) | 0.009 |
| Labs | ||||
| ALT (IU/L) | 52 (38–68) | 55 (40.5–70.5) | 40 (32–68) | 0.34 |
| LDL (mg/dL) | 120 (85–154) | 120 (80–134) | 120 (97–137) | 0.74 |
| HDL (mg/dL) | 43 (32.5–51.5) | 44 (39–55) | 34 (33–40) | 0.01 |
| TG (mg/dL) | 172.5 (122–227) | 148 (112–222) | 231 (180–462) | 0.03 |
| HgA1c | 5.8 (5.3–6.8) | 5.9 (5.3–6.7) | 5.7 (5.4–9) | 0.30 |
| Fibroscan | ||||
| Liver stiffness (kPa) | 7.15 (4.9–11.8) | 7 (4.8–10.3) | 9.6 (6.3–26.7) | 0.12 |
| Fibrosis stage | 0.54 | |||
| F0-2 | 22 (59%) | 19 (63%) | 4 (57%) | |
| F3 | 4 (11%) | 3 (10%) | 1 (14%) | |
| F4 | 11 (30%) | 8 (27%) | 2 (28%) | |
| CAP score | 329 (288–370) | 327.5 (278–356) | 362 (312–379) | 0.21 |
| Physical activity and function | ||||
| Moderate/vigorous intensity physical activity (median days/week)^ | 0 (0–2) | 0 (0–2) | 0 (0–2) | 1.0 |
| 6MWT distance (feet) | 1515 (1312–1800) | 1585 (1295–1822) | 1420 (1328–1536) | 0.30 |
| Post-test dyspnea (Borg scale: 0–10) | 2 (0–3) | 2 (0–3) | 1 (0.5–4) | 0.95 |
| HRQOL: T-score* (SD) | ||||
| Physical function | 49.9 (9.8) | |||
| Ability to participate in social roles | 56.2 (10.0) | |||
| Satisfaction with social roles | 50.2 (9.2) | |||
| Psychosocial illness impact | 48.9 (11.9) | |||
| Fatigue | 54.1 (10.2) | |||
Bolded values indicate result was significant with P value of 0.05 or less
BMI Body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, LDL low density lipoprotein, HDL high density lipoprotein, TG triglycerides, HgA1c hemoglobin A1c, 6MWT 6-min walk test, IQR interquartile range, SD standard deviation
*T-scores (mean = 50; SD = 10) are presented for each PROMIS domain. Higher scores for symptom domains (fatigue, psychosocial illness) indicate a higher symptom burden. Higher scores for functioning domains (physical function, ability to participate in social roles, satisfaction with social roles) indicate good functioning
^Measured using IPAQ